A phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma (R3767-ONC-22122)
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called “study drugs”. The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children.
Main Inclusion/Exclusion:
- NO prior systemic therapy for unresectable or metastatic melanoma
- NO prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1
Indications:
- Unresectable or Metastatic Melanoma
Contact: cajwciclinicaltrials@providence.org